Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Burley, T.A., Da Pieve, C., Martins, C.D., Ciobota, D.M., Allott, L., Oyen, W.J., Harrington, K.J., Smith, G. & Kramer-Marek, G. (2019). Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models. J nucl med, Vol.60 (3), pp. 353-361.  show abstract

Burley, T.A., Mączyńska, J., Shah, A., Szopa, W., Harrington, K.J., Boult, J.K., Mrozek-Wilczkiewicz, A., Vinci, M., Bamber, J.C., Kaspera, W., et al. (2018). Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment. Int j cancer, Vol.142 (11), pp. 2363-2374.  show abstract

Martins, C.D., Kramer-Marek, G. & Oyen, W.J. (2018). Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert opin drug deliv, Vol.15 (2), pp. 185-196.  show abstract

Martins, C.D., Da Pieve, C., Burley, T.A., Smith, R., Ciobota, D.M., Allott, L., Harrington, K.J., Oyen, W.J., Smith, G. & Kramer-Marek, G., et al. (2018). HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. Clin cancer res, Vol.24 (8), pp. 1853-1865.  show abstract

King, A., Doepner, A., Turton, D., Ciobota, D.M., Da Pieve, C., Wong Te Fong, A.-., Kramer-Marek, G., Chung, Y.-. & Smith, G. (2018). Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure. Org biomol chem, Vol.16 (16), pp. 2986-2996.  show abstract

Baker, L.C., Sikka, A., Price, J.M., Boult, J.K., Lepicard, E.Y., Box, G., Jamin, Y., Spinks, T.J., Kramer-Marek, G., Leach, M.O., et al. (2018). Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. Front oncol, Vol.8, p. 271.  show abstract

Allott, L., Da Pieve, C., Meyers, J., Spinks, T., Ciobota, D.M., Kramer-Marek, G. & Smith, G. (2017). Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. Chem commun (camb), Vol.53 (61), pp. 8529-8532.  show abstract

Szopa, W., Burley, T.A., Kramer-Marek, G. & Kaspera, W. (2017). Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. Biomed res int, Vol.2017, p. 8013575.  show abstract

Mansfield, D.C., Kyula, J.N., Rosenfelder, N., Chao-Chu, J., Kramer-Marek, G., Khan, A.A., Roulstone, V., McLaughlin, M., Melcher, A.A., Vile, R.G., et al. (2016). Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene ther, Vol.23 (4), pp. 357-368.  show abstract

Kramer-Marek, G. & Oyen, W.J. (2016). Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside. J nucl med, Vol.57 (7), pp. 996-1001.

Denis-Bacelar, A.M., Cronin, S.E., Da Pieve, C., Paul, R.L., Eccles, S.A., Spinks, T.J., Box, C., Hall, A., Sosabowski, J.K., Kramer-Marek, G., et al. (2016). Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers. Ejnmmi res, Vol.6 (1), p. 85.  show abstract

Da Pieve, C., Allott, L., Martins, C.D., Vardon, A., Ciobota, D.M., Kramer-Marek, G. & Smith, G. (2016). Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors. Bioconjug chem, Vol.27 (8), pp. 1839-1849.  show abstract

Xu, Z., Bagci, U., Mansoor, A., Kramer-Marek, G., Luna, B., Kubler, A., Dey, B., Foster, B., Papadakis, G.Z., Camp, J.V., et al. (2015). Computer-aided pulmonary image analysis in small animal models. Med phys, Vol.42 (7), pp. 3896-3910.  show abstract

Adesina, S.K., Holly, A., Kramer-Marek, G., Capala, J. & Akala, E.O. (2014). Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies. J pharm sci, Vol.103 (8), pp. 2546-2555.  show abstract

Mohd Nafi, S.N., Generali, D., Kramer-Marek, G., Gijsen, M., Strina, C., Cappelletti, M., Andreis, D., Haider, S., Li, J.-., Bridges, E., et al. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, Vol.5 (15), pp. 5934-5949.  show abstract

Nafi, S., Generali, D., Kramer-Marek, G., Gijsen, M., Strina, C., Cappelletti, M., Andreis, D., Haider, S., Li, J.L., Bridges, E., et al. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget, .  show abstract

Feldinger, K., Generali, D., Kramer-Marek, G., Gijsen, M., Ng, T.B., Wong, J.H., Strina, C., Cappelletti, M., Andreis, D., Li, J.-., et al. (2014). ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget, Vol.5 (16), pp. 6633-6646.  show abstract

Kramer-Marek, G., Gore, J. & Korc, M. (2013). Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer lett, Vol.341 (2), pp. 132-138.  show abstract

Bagci, U., Kramer-Marek, G. & Mollura, D.J. (2013). Automated computer quantification of breast cancer in small-animal models using PET-guided MR image co-segmentation. Ejnmmi res, Vol.3 (1), p. 49.  show abstract

Capala, J., Kong, A., Kramer-Marek, G. & Gijsen, M. (2012). Reply. J nucl med, .

Kramer-Marek, G., Gijsen, M., Kiesewetter, D.O., Bennett, R., Roxanis, I., Zielinski, R., Kong, A. & Capala, J. (2012). Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J nucl med, Vol.53 (4), pp. 629-637.  show abstract

Kramer-Marek, G. & Capala, J. (2012). The role of nuclear medicine in modern therapy of cancer. Tumor biology, Vol.33 (3), pp. 629-640.

Kramer-Marek, G., Bernardo, M., Kiesewetter, D.O., Bagci, U., Kuban, M., Aras, O., Zielinski, R., Seidel, J., Choyke, P. & Capala, J., et al. (2012). PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG. J nucl med, Vol.53 (6), pp. 939-946.  show abstract

Mitsunaga, M., Nakajima, T., Sano, K., Kramer-Marek, G., Choyke, P.L. & Kobayashi, H. (2012). Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. Bmc cancer, Vol.12, p. 345.  show abstract

Kramer-Marek, G., Longmire, M.R., Choyke, P.L. & Kobayashi, H. (2012). Recent Advances in Optical Cancer Imaging of EGF Receptors. Current medicinal chemistry, Vol.19 (28), pp. 4759-4766.

Jagoda, E.M., Lang, L., Bhadrasetty, V., Histed, S., Williams, M., Kramer-Marek, G., Mena, E., Rosenblum, L., Marik, J., Tinianow, J.N., et al. (2012). Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J nucl med, Vol.53 (10), pp. 1592-1600.  show abstract

Kramer-Marek, G. & Capala, J. (2012). Can PET imaging facilitate optimization of cancer therapies?. Curr pharm des, Vol.18 (18), pp. 2657-2669.  show abstract

Dahl, M., Bouchelouche, P., Kramer-Marek, G., Capala, J., Nordling, J. & Bouchelouche, K. (2011). Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Molecular biology reports, Vol.38 (7), pp. 4237-4243.

Kramer-Marek, G., Shenoy, N., Seidel, J., Griffiths, G.L., Choyke, P. & Capala, J. (2011). 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur j nucl med mol imaging, Vol.38 (11), pp. 1967-1976.  show abstract

Kramer-Marek, G., Shenoy, N., Seidel, J., Griffiths, G., Choyke, P. & Capala, J. (2011). Ga-68-radiolabeled DOTA-affibody molecule for in vivo assessment of HER2 expression with PET. Cancer research, Vol.71.

Gijsen, M., Kramer-Marek, G., Bennett, R., Harris, A., Capala, J. & Kong, A. (2011). Trastuzumab treatment induces ADAM17 and HER ligands in vivo. Cancer research, Vol.71.

Jagoda, E., Bhadrasetty, V., Lixin, L., Williams, M., Histed, S., Gabriela, K.-., Marik, J., Tinianow, J., Merchant, M., Szajek, L., et al. (2011). Comparison of [Zr-89] and [Br-76] labeled MetMAb, a one-armed monoclonal antibody targeting the Met receptor tyrosine kinase (Met), in human gastric carcinoma (MKN-45) and glioblastoma (U87 MG) cells and xenografts. Journal of labelled compounds & radiopharmaceuticals, Vol.54, pp. S172-S172.

Lyakhov, I., Kuban, M., Zielinski, R., Kramer-Marek, G. & Capala, J. (2010). HER2-and EGFR-specific Affiprobes - Novel recombinant optical probes for cell imaging. Cancer research, Vol.70.

Lyakhov, I., Zielinski, R., Kuban, M., Kramer-Marek, G., Fisher, R., Chertov, O., Bindu, L. & Capala, J. (2010). HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem, Vol.11 (3), pp. 345-350.  show abstract

Watson, R.P., Kramer-Marek, G. & Capala, J. (2010). Instrumental neutron activation analysis of gold in mouse tissues. Abstracts of papers of the american chemical society, Vol.240.

Morgan, N.Y., Kramer-Marek, G., Smith, P.D., Camphausen, K. & Capala, J. (2009). Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters. Radiat res, Vol.171 (2), pp. 236-244.  show abstract

Nawalany, K., Rusin, A., Kepczyński, M., Mikhailov, A., Kramer-Marek, G., Snietura, M., Połtowicz, J., Krawczyk, Z. & Nowakowska, M. (2009). Comparison of photodynamic efficacy of tetraarylporphyrin pegylated or encapsulated in liposomes: in vitro studies. J photochem photobiol b, Vol.97 (1), pp. 8-17.  show abstract

Kramer-Marek, G., Kiesewetter, D.O. & Capala, J. (2009). Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J nucl med, Vol.50 (7), pp. 1131-1139.  show abstract

Zielinski, R., Lyakhov, I., Jacobs, A., Chertov, O., Kramer-Marek, G., Francella, N., Stephen, A., Fisher, R., Blumenthal, R. & Capala, J., et al. (2009). Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J immunother, Vol.32 (8), pp. 817-825.  show abstract

Capala, J., Kramer-Marek, G., Lee, S.B., Hassan, M., Kiesewetter, D.O., Puri, A., Chernomordik, V., Gandjbakhche, A., Griffiths, G. & Blumenthal, R., et al. (2009). Molecular targeting of HER2 for diagnosis and therapy of breast cancer. Cancer research, Vol.69 (2), pp. 349S-349S.

Watson, R., Popelka-Filcoff, R., Kramer-Marek, G., Mackey, E.A., Spatz, R.O. & Capala, J. (2009). ANYL 96-Quantitation of gold in biological tissues using neutron activation analysis. Abstracts of papers of the american chemical society, Vol.238.

Kramer-Marek, G., Kiesewetter, D.O., Martiniova, L., Jagoda, E., Lee, S.B. & Capala, J. (2008). [18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur j nucl med mol imaging, Vol.35 (5), pp. 1008-1018.  show abstract

Kiesewetter, D.O., Krämer-Marek, G., Ma, Y. & Capala, J. (2008). Radiolabeling of HER2 specific Affibody(R) molecule with F-18. J fluor chem, Vol.129 (9), pp. 799-805.  show abstract

Lee, S.B., Hassan, M., Fisher, R., Chertov, O., Chernomordik, V., Kramer-Marek, G., Gandjbakhche, A. & Capala, J. (2008). Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin cancer res, Vol.14 (12), pp. 3840-3849.  show abstract

Puri, A., Kramer-Marek, G., Campbell-Massa, R., Yavlovich, A., Tele, S.C., Lee, S.-., Clogston, J.D., Patri, A.K., Blumenthal, R. & Capala, J., et al. (2008). HER2-Specific Affibody-Conjugated Thermosensitive Liposomes (Affisomes) for Improved Delivery of Anticancer Agents. Journal of liposome research, Vol.18 (4), pp. 293-307.

Kramer-Marek, G., Kiesewetter, D.O., Martiniova, L., Rodriguez, Y. & Capala, J. (2007). F-18-Z(HER2)-Affibody: A new tracer for molecular imaging of HER2-expressing tumors by PET. Molecular cancer therapeutics, Vol.6 (12), pp. 3478S-3478S.

Oyen, W. & kramer-marek, G. Radioimmunotherapy for delivery of cytotoxic radioisotopes - current status and challenges. Expert opinion on drug delivery, .


Conferences

King, A., Doepner, A., Turton, D., Ciobota, D., Kramer-Marek, G. & Smith, G. (2018). Synthesis and evaluation of 18F-radiolabeled anticancer agents as tracers of nucleic acid metabolism, ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol.256.

Turnock, S.M., Turton, D.R., Ciobota, D.M., Yogev, O., Chesler, L., Wilson, T., Gouverneur, V., Smith, G. & Kramer-Marek, G. (2017). Potential of PET imaging to monitor upregulation of NET-1 transporter, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.44, p.S410.

Da Pieve, C., Allott, L., Martins, C.D., Carroll, L., Paul, R.L., Aboagye, E.O., Kramer-Marek, G. & Smith, G. (2015). Strategies for the development of high specific activity affibody based probes for the detection of HER3 positive tumours, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.42, pp.S247-S248.

Martins, C.D., Da Pieve, C., Ciobota, D.M., Paul, R.L., Spinks, T., Smith, G. & Kramer-Marek, G. (2015). Broadcasting the HER3 receptor status in vivo, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.42, p.S262.

Burley, T., Martins, C.D., Da Pieve, C., Paul, R.L., Ciobota, D.M., Smith, G., Harrington, K. & Kramer-Marek, G. (2015). 89Zr-Affibody for specific detection of EGFR expression in HNSCC, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.42, p.S247.

Price, J.M., Baker, L.C., Boult, J.K., Box, C., Kramer-Marek, G., Murray, I., Robinson, S.P. & Leach, M.O. (2014). 18F-fluorodeoxyglucose (FDG) uptake is increased in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistant compared with sensitive head and neck cancer xenografts, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol.41, p.S638.

Wright, C.E., Jagoda, E., Cecchi, F., Bhadrasetty, V., Histed, S., Williams, M., Kramer-Marek, G., Mena, E., Rosenblum, L., Lang, L., et al. (2013). Developing a molecular imaging agent for Met using onartuzumab (MetMAb)., JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Nafi, S.M., Kong, A., Gijsen, M., Kramer-Marek, G. & Capala, J. (2012). Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer, EUROPEAN JOURNAL OF CANCER, Vol.48, p.126.

Dahl, M., Bouchelouche, P., Kramer-Marek, G., Capala, J., Nordling, J. & Bouchelouche, K. (2010). SARCOSINE INDUCES INCREASE IN HER2/NEU EXPRESSION IN PROSTATE CANCER CELLS, EUROPEAN UROLOGY SUPPLEMENTS, Vol.9 (2), p.272.

Dahl, M., Bouchelouche, P., Kramer-Marek, G., Capala, J. & Bouchelouche, K. (2010). Effect of tumour necrosis factor (TNF) alpha on HER2/neu expression in ovarian cancer cells, EJC SUPPLEMENTS, Vol.8 (5), p.180.

Dahl, M., Bouchelouche, P., Kramer-Marek, G., Capala, J., Nordling, J. & Bouchelouche, K. (2010). Sarcosine induces up-regulation of HER2/neu in androgen dependent prostate cancer cells, EJC SUPPLEMENTS, Vol.8 (5), p.179.

Capala, J., Kramer-Marek, G. & Kiesewetter, D. (2010). IN VIVO QUANTIFICATION OF CHANGES IN HER2 EXPRESSION FOLLOWING THERAPEUTIC INTERVENTION, ANNALS OF ONCOLOGY, Vol.21, pp.40-41.

Kiesewetter, D.O., Kramer-Marek, G., Ma, Y. & Capala, J. (2008). INOR 665-Radiolabeling of HER2 specific Affibody (R) molecule with F-18, ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, Vol.236.


Patents and patent applications

Kramer-Marek, Radiolabeled Affibody® Molecules.US 8,303,960 B2.